Keeping Current

  • Author: Vários
  • Narrator: Vários
  • Publisher: Podcast
  • Duration: 292:11:45
  • More information

Informações:

Synopsis

Experts discuss relevant and actionable strategies for practice improvement as well as timely clinical topics.

Episodes

  • Complement in Rare Kidney Diseases: Different Diseases With a Common Denominator

    29/06/2022 Duration: 31min

    How familiar are you with the role of complement pathways in the pathophysiology and management of complement-mediated kidney diseases? Credit available for this activity expires: 6/28/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/976176?src=mkm_podcast_addon_976176

  • My Challenges and Hopes for a Better Life With Major Depressive Disorder: The Voice of the Patient

    29/06/2022 Duration: 28min

    Did you know that more than 50% of physicians experience burnout and that burnout can lead to a loss of compassion? Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/976001?src=mkm_podcast_addon_976001

  • Obesity Talk (Episode 2): Opportunities for the Use of Novel Anti-Obesity Medications in Clinical Practice?

    28/06/2022 Duration: 20min

    Are you up-to-date regarding benefits of novel anti-obesity drugs in people with obesity? Join Drs Sharma and Macklin to improve your knowledge. Credit available for this activity expires: 6/27/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/976164?src=mkm_podcast_addon_976164

  • Optimizing Outcomes With Biologic Therapies in Psoriatic Disease

    28/06/2022 Duration: 51min

    Did you know that we could be undertreating patients with psoriasis? Credit available for this activity expires: 6/24/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/976067?src=mkm_podcast_addon_976067

  • Seismic Shifts in Heart Failure Management: How Sodium-Glucose Cotransporter-2 Inhibitors Are Changing How We Treat Our Patients

    27/06/2022 Duration: 43min

    International expert faculty discuss how sodium-glucose cotransporter-2 (SGLT2) inhibitors have changed the management of patients with heart failure (HF). Credit available for this activity expires: [06/24/23] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/976002?src=mkm_podcast_addon_976002

  • Targeting Angiopoietin-2: A New Approach in Retinal Diseases

    24/06/2022 Duration: 26min

    Can anything improve anti-vascular epithelial growth factor (anti-VEGF) control of exudation in retinal disease? Learn how targeting the angiopoietin pathway may help. Credit available for this activity expires: 6/23/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975535?src=mkm_podcast_addon_975535

  • How to Assess and Diagnose Food Allergies: Experts Discuss Best Practices and Recent Advancements

    23/06/2022 Duration: 34min

    With incidence of food-induced anaphylaxis on the increase, are you up to date on how best to diagnose and manage patients with food allergies? Credit available for this activity expires: 6/21/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975719?src=mkm_podcast_addon_975719

  • Advanced Age-Related Macular Degeneration: Assessment, Strategies, and New Therapies

    21/06/2022 Duration: 31min

    Do you know the best imaging modalities to diagnose advanced age-related macular degeneration (AMD) and track its progress? Learn how to assess patients and how to discuss with them what the future may hold. Credit available for this activity expires: 6/17/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975758?src=mkm_podcast_addon_975758

  • Novel Therapies for NSCLC With EGFR Exon 20 Insertions: Practical Pearls for the Clinic

    21/06/2022 Duration: 41min

    Are you aware that there are now targeted therapies available for patients harboring exon 20 insertions, the third most common type of EGFR mutation in non-small cell lung cancer (NSCLC)? Credit available for this activity expires: 6/20/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975726?src=mkm_podcast_addon_975726

  • Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives

    17/06/2022 Duration: 40min

    Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC. Credit available for this activity expires: 6/15/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532

  • Clinical Perspectives on HER2-Targeted Antibody-Drug Conjugates: Treatment-Related Adverse Events

    15/06/2022 Duration: 37min

    Do you know how to safely manage treatment-related adverse events (TRAEs) associated with human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs)? Credit available for this activity expires: 6/14/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975383?src=mkm_podcast_addon_975383

  • International Heart Failure Guidelines and the Latest Data: Out of Complexities, Simplicities Emerge With SGLT2 Inhibitors

    14/06/2022 Duration: 33min

    What do the latest guidelines say about HF management? Drs Butler, Bozkurt, and McDonagh discuss. Credit available for this activity expires: 6/13/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975310?src=mkm_podcast_addon_975310

  • Epilepsy and Depression: Early Recognition or Double Trouble?

    13/06/2022 Duration: 34min

    Do you know how and when to screen for depression in people with epilepsy, and when to manage depression and when to refer? Credit available for this activity expires: 6/10/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975275?src=mkm_podcast_addon_975275

  • Addressing the Challenge of Endocrine-Resistant Breast Cancer

    02/06/2022 Duration: 37min

    Did you know that estrogen receptor-positive breast cancer often develops treatment resistance to endocrine therapy? Credit available for this activity expires: 5/31/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/974726?src=mkm_podcast_addon_974726

  • Addressing the Challenge of HER2 Heterogeneity in Breast Cancer

    01/06/2022 Duration: 34min

    Did you know that there is a paradigm shift in the definition of human epidermal growth factor receptor 2 (HER2) status in breast cancer? Credit available for this activity expires: 5/31/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/974715?src=mkm_podcast_addon_974715

  • Management Strategies to Optimize Outcomes in CKD-aP: A Case-Based Discussion

    27/05/2022 Duration: 34min

    How well are you managing pruritus in your patients on dialysis? Join this activity to learn about latest developments in chronic kidney disease-associated pruritus (CKD-aP). Credit available for this activity expires: 5/26/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/973462?src=mkm_podcast_addon_973462

  • RSV: Omnipresent and Inescapable

    27/05/2022 Duration: 18min

    Did you know that 3.5 million children are hospitalized each year with a respiratory syncytial virus (RSV) infection, but the true burden is unknown due to a lack of diagnosis? Credit available for this activity expires: 5/26/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/974410?src=mkm_podcast_addon_974410

  • The Molecular Tumor Board: Best Practices for Managing Primary and Acquired EGFR TKI Resistance

    24/05/2022 Duration: 45min

    Do you know that primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) occurs in approximately 20% to 30% of patients with EGFR-mutated non-small cell lung cancer (NSCLC), and acquired resistance is inevitable? Credit available for this activity expires: 5/23/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/974097?src=mkm_podcast_addon_974097

  • The Implications of the Latest Data on SGLT2 Inhibitors in Heart Failure: A Unified Approach to Treatment?

    17/05/2022 Duration: 29min

    Drs Zieroth and Anker discuss heart failure (HF) outcome trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors. Credit available for this activity expires: 5/17/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/972924?src=mkm_podcast_addon_972924

  • Managing Psoriatic Disease With Biologic Therapies

    12/05/2022 Duration: 35min

    Did you know that over the past years, the percentage of patients who report entheseal involvement in clinical studies has almost doubled from approximately 30% to 60%? Credit available for this activity expires: 5/10/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/973518?src=mkm_podcast_addon_973518

page 13 from 27